Fig 1: (A): Top, tSNE graph of myeloid subpopulations represented by different colors. NK/NK-T cells: CD11b+, CD56+, CD14-, CD66b-. LDNs: CD11b+, CD66b+, CD116+, CD14-. Monocytes/macrophages: CD11b+, CD14+, CD116+, CD66b-. Lower left, tSNE graph of 3 responders to immune checkpoint inhibitors (ICI) monotherapy. Lower right, tSNE graph representative of 3 non-responders to ICI monotherapy. (B): Left, ROC analysis of baseline low-density neutrophils (LDNs) as a function of clinical benefit rate (CBR) < 6 months. Right, baseline levels of LDN in patients receiving ICI monotherapy with CBR longer than 6 months compared with patients with CBR less than 6 months and with healthy donors. (C): Top, progression free survival stratified by the presence of baseline LDNs above the ROC threshold (7.09%). Below, overall survival stratified by the presence of baseline LDN above the ROC threshold. *** indicate highly significant (p < 0.001) statistical differences.